Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Cancer Research and Treatment : Official Journal of Korean Cancer Association, December 2016

28052657

Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim

The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer (NSCLC) patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities. From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities: thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (Group I); CCRT plus consolidation CTx (Group II); and CTx alone (Group III). TRT was delivered to 155 patients (Groups I/II), and full dose CTx was delivered to 172 patients either as a consolidative or a sole modality (Group II/III). During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS) and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4% and 29.6%, respectively. There was no difference in OS among groups. TRT (Groups I/II) significantly improved LRC, full dose CTx (Groups II/III) did DMFS, and CCRT plus consolidation CTx (Group II) did DFS, respectively. The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.